---
title: "Varegacestat (AL102) in Desmoid tumors: Special populations"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Special populations. Topics: Hepatic impairment: single-dose pharmacokinetic study design; Hepatic and renal function thresholds for trial eligibility; Pregnancy, breastfeeding, and contraception; Ovarian toxicity in premenopausal women; 3 further topics. 7 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/special-populations"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Hepatic impairment: single-dose pharmacokinetic study design

> “This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.”
> “This is an open-label, single-dose, parallel study to evaluate the effects of varying degrees of impaired hepatic function on the PK, safety, and tolerability of varegacestat in adult participants.”
> “The study will enroll participants with mild (Group 2) and moderate (Group 3) hepatic impairment (HI) and healthy participants with normal hepatic function (Group 1) at a 1:1 ratio.”
> “Subsequently, if appropriate, the study will enroll participants with severe (Group 4) HI and healthy participants with normal hepatic function (Group 1), as needed, to provide 1:1 matches for Group 4. The decision to conduct Group 4 enrollment will be contingent upon the assessment of the feasibility, PK, and safety data from Groups 1-3.”
> “Has a score on the Child-Pugh scale at screening visit and confirmed at check-in as follows:”
> “Mild: ≥5 and ≤6 [Category A]; or”
> “Moderate: ≥7 and ≤9 [Category B]; or”
> “Severe: ≥10 and ≤15 [Category C].”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="topic-2.1.2.8-2"></a>

### Hepatic and renal function thresholds for trial eligibility

> “Abnormal organ and marrow function at Screening defined as:”
> “Total bilirubin >1.5x upper limit of normal (ULN) (except known Gilbert's syndrome),”
> “Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >2.5x ULN,”
> “Serum creatinine > ULN and creatinine clearance (CrCl) <60 mL/min (calculation of CrCl will be based on acceptable institution standard)”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-2.1.2.8-3"></a>

### Pregnancy, breastfeeding, and contraception

> “Pregnant or breastfeeding or expecting to conceive children within the projected duration of the study.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

> “Lactating or pregnant women were not eligible and all subjects were needed to comply with effective contraception methods as per protocol.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

> “Healthy, adult, male or female (of non-childbearing potential only), 18 to 55 years of age, inclusive, at the screening visit.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

> “Male participants must follow protocol-specified contraception guidance”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="topic-2.1.2.8-4"></a>

### Ovarian toxicity in premenopausal women

> “36/53 (67.9)”
> “A known class effect of GSI”
> “Varegacestat 56% | Placebo 5% of premenopausal women”
> “No women discontinued varegacestat due to ovarian toxicity”
> “Ovarian toxicity resolved in all participants with follow-up data after stopping treatment”
> “Ovarian toxicity includes the MedDRA preferred terms amenorrhea, premature menopause, menopause, ovarian failure.”
> “20 of 36 premenopausal women with ovarian toxicity (56%)”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

| Treatment disposition | Ovarian toxicity resolution |
| --- | --- |
| “8 off varegacestat, follow-up available” | “OT resolved in 8 (100%)” |
| “10 ongoing varegacestat” | “OT resolved in 3 (30%)”; “OT unresolved in 7 (70%)” |
| “2 off study, no follow-up available” | “OT resolution status unknown” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “Ovarian toxicity included amenorrhea, premature menopause, menopause, and ovarian failure; and all were Grade 2.”

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

<a id="topic-2.1.2.8-5"></a>

### Age: eligibility and enrolled age ranges

> “At least 18 years of age (inclusive) at the time of signing the informed consent form (ICF).”
> “≥12 years of age (inclusive) and ≥ 40 kg at the time of signing the ICF.”
> “Minor subjects must be capable of giving written assent as appropriate per the applicable age (per local regulatory requirements).”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

| Population | Age (years), median (min-max) |
| --- | --- |
| Efficacy population, varegacestat (RINGSIDE Parts A and B), N = 121 | “40 (18-72)” |
| Efficacy population, placebo (RINGSIDE Part B), N = 77 | “39 (20-69)” |
| Safety population, varegacestat (CA002-001 and RINGSIDE), N = 157 | “45 (18-84)” |

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

<a id="topic-2.1.2.8-6"></a>

### Age subgroups: objective response

> “We performed descriptive analyses of objective response rate (ORR) in the following subgroups with at least 5 participants: age (≤40 years vs. >40 years), tumor size (<70 mm vs. ≥70 mm), prior lines of therapy (0, 1, or 2+), tumor location (intra-abdominal vs. extra-abdominal) and mutational biomarkers (APC vs CTNNB1).”
> “Age ≤40 years (n=22) vs. >40 years (n=14)”
> “13 (59) vs. 10 (71)”
> “Response rates were comparable across all subgroups examined.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-2.1.2.8-7"></a>

### Age subgroups: progression-free survival

> “PFS consistently favored VAR in all subgroups analyzed.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Consistent PFS Benefit with Varegacestat Across Subgroups”
> “≤ 30 years”
> “> 30 years”
> “Post-hoc subgroup analysis to evaluate patients with poor prognosis”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
